Zacks6d agobullish
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
Zacks6d agoneutral
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in FocusAngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
Zacks6d agobullish
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.
24/7 Wall St.15d agoneutral
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and MoreWall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.
The Wall Street Journal22d agoneutral
Altana Acquires AI Platform to Tackle Customs ComplexityThe trade tech company says Cervo AI can speed up customs brokerage tasks as tariff and trade policies shift.
Insider Monkey50d agoneutral
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]
Zacks75d agoneutral
Teleflex Divestitures: What Investors Should Watch in 2026TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.